Ankylosing Spondylitis: treatment paradigm and role of JAKi in the treatment of active ankylosing spondylitis

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Ankylosing Spondylitis: Treatment Paradigm and Role of JAKi in the Treatment of Active Ankylosing Spondylitis.
Ankylosing spondylitis (AS) is a chronic inflammatory disorder that primarily targets the spine and sacroiliac joints, causing significant pain and stiffness. The treatment approach usually begins with nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and alleviate pain. Physical therapy plays a crucial role in maintaining flexibility and improving posture. For more severe cases, biologic therapies like TNF inhibitors are often used to control inflammation. Early intervention and a comprehensive treatment plan are essential to managing symptoms and slowing disease progression.
JAK inhibitors (JAKi) have recently gained attention as an effective treatment for active ankylosing spondylitis, especially in patients who do not respond well to conventional therapies. These medications work by blocking the Janus kinase pathway, a key player in the inflammatory process of AS. By inhibiting this pathway, JAKi help reduce inflammation, decrease pain, and improve physical function. Clinical studies have shown promising results, indicating significant improvement in disease activity and patient quality of life. As a result, JAK inhibitors are becoming an important addition to the therapeutic options for active AS.
Therefore, get an overall knowledge of ankylosing Spondylitis: treatment paradigm and role of JAKi in the treatment of active ankylosing spondyli

See More Webinars @ Hidoc Webinars